Immunome, Inc.
Symbol: IMNM (NASDAQ)
15.93
▼ (-4.87%) -0.815
Company Description:
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Key Stats
- Today's Open: $16.87
- Today's High: $17.297
- Today's Low: $15.125
- Today's Volume: 1.68M
- Yesterday Close: $16.74
- Yesterday High: $16.815
- Yesterday Low: $15.94
- Yesterday Volume: 1.00M
- Last Min Volume: 0
- Last Min High: $15.925
- Last Min Low: $15.879
- Last Min VWAP: $0
Company Profile
- Name: Immunome, Inc.
- Website: https://www.immunome.com
- Listed Date: 2020-10-02
- Location: BOTHELL, WA
- Market Status: Active
- CIK Number: 0001472012
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.46B
- Round Lot: 100
- Outstanding Shares: 87.05M
- Asset Type: CS
RECENT FILINGS FOR IMNM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-07 | SCHEDULE 13G/A | View |
| 2025-09-11 | 4 | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-11 | 8-K | View |
Latest News on IMNM